Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation

World Journal of Gastroenterology

Volumn 21, Issue 36, 2015, Pages 10290-10298

  Ishigami, Masatoshi ^a   Ogura, Yasuhiro ^a   Hirooka, Yoshiki ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Escape mutant; Hepatitis B immunoglobulin; Hepatitis B vaccine; Hepatitis B virus; Liver transplantation; Nucleos(t)ide analogue; Prophylaxis

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

COST CONTROL; GOLD STANDARD; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIVER TRANSPLANTATION; LONG TERM CARE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MUTANT; PATIENT CARE; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT VIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ADVERSE EFFECTS; COMPLICATION; DRUG EFFECTS; END STAGE LIVER DISEASE; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MUTATION; PATHOGENICITY; PHENOTYPE; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; END STAGE LIVER DISEASE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MUTATION; PHENOTYPE; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84942311882     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i36.10290     Document Type: Review

References (96)

1. WHO. Hepatitis B, 2015. Available from: URL: http://www.who. int/mediacentre/factsheets/fs204/en/
2. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI, Tong MJ, Busuttil RW. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-1534 [PMID: 19877207 DOI: 10.1002/lt.21882]
3. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937 [PMID: 17383422]
4. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013; 19: 268-274 [PMID: 23447403 DOI: 10.1002/lt.23600]
5. Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-509 [PMID: 19802696 DOI: 10.1007/s10620-009-0999-6]
6. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85 [PMID: 15382222]
7. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, Lerut J, Salizzoni M, Pollard S, Muhlbacher F, Rogiers X, Garcia Valdecasas JC, Berenguer J, Jaeck D, Moreno Gonzalez E. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-1243 [PMID: 14625822]
8. Camci C, Gurakar A, Rose J, Rizvi S, Wright H, Bader T, Monlux R, Schade RR, Nour BM, Sebastian A. Liver transplantation for hepatitis B in the United States. Transplant Proc 2005; 37: 4350-4353 [PMID: 16387118]
9. The Japanese Liver Transplant Society. Liver Transplantation in Japan.?Registry of the Japanese Liver Transplantation Society. Jpn J Transpl (in Japanese) 2011; 47: 416-427
10. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park JI, Ryu JH, Lee HJ, Suh DJ, Lim YS. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 2008; 14: 770-778 [PMID: 18508369 DOI: 10.1002/lt.21440]
11. Gao YJ, Zhang M, Jin B, Meng FP, Ma XM, Liu ZW, Su HB, Zhao JM, Li HW. Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. J Gastroenterol Hepatol 2014; 29: 554-560 [PMID: 24117714 DOI: 10.1111/jgh.12404]
12. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075 [PMID: 17393513]
13. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.e1-2 [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063]
14. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardí R, Cruz de Castro E, García-Rey C. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with longterm lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817 [PMID: 12763375]
15. Cholongi tas E, Papa theodor idi s GV. Revi ew of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19: 9189-9197 [PMID: 24409047 DOI: 10.3748/wjg.v19.i48.9189]
16. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010; 58: 258-266 [PMID: 20116937 DOI: 10.1016/j.patbio.2009.11.001]
17. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-1764 [PMID: 22157327 DOI: 10.1136/gutjnl-2011-301073]
18. Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol 2005; 139: 2-10 [PMID: 15606606]
19. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626 [PMID: 2010156]
20. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, Alexander GJ, Williams R. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-111 [PMID: 1737910]
21. Lauchart W, Müller R, Pichlmayr R. Lo n g-t e rm immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 4051-4053 [PMID: 3313997]
22. Müller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, Lautz HU, Böker K, Stangel W. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13: 90-96 [PMID: 1918881]
23. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, Bismuth H. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-815 [PMID: 1672913]
24. Eason JD, Freeman RB, Rohrer RJ, Lewis WD, Jenkins R, Dienstag J, Cosimi AB. Should liver transplantation be performed for patients with hepatitis B? Transplantation 1994; 57: 1588-1593 [PMID: 8009592]
25. Demetris AJ, Jaffe R, Sheahan DG, Burnham J, Spero J, Iwatsuki S, Van Theil DH, Starzl TE. Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol 1986; 125: 161-172 [PMID: 3535528]
26. Shah G, Demetris AJ, Gavaler JS, Lewis JH, Todo S, Starzl TE, Van Thiel DH. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology 1992; 103: 323-329 [PMID: 1612340]
27. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157 [PMID: 1988336]
28. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med 1989; 321: 1092-1099 [PMID: 2677722]
29. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847 [PMID: 8247035]
30. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190 [PMID: 21656655 DOI: 10.1002/lt.22354]
31. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, Dussaix E, Guettier C, Bismuth H, Samuel D. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 86-95 [PMID: 12829990]
32. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195 [PMID: 11093723]
33. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333 [PMID: 8938155]
34. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, Caldwell SH, Pruett TL. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364 [PMID: 8629297]
35. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, Ryan TS, Kuhns M, McNamara A, Caldwell SH, Abdulkareem A, Pruett TL. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-850 [PMID: 9637547]
36. Hadziyannis SJ. Milestones and perspectives in viral hepatitis B. Liver Int 2011; 31 Suppl 1: 129-134 [PMID: 21205150 DOI: 10.1111/j.1478-3231.2010.02406.x]
37. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263 [PMID: 10528035]
38. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-896 [PMID: 10051494]
39. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215 [PMID: 8898039]
40. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 809-815 [PMID: 11003363]
41. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, Fan ST, Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233: 276-281 [PMID: 11176135]
42. Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, Levy GA, Lilly LB. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69: 1403-1407 [PMID: 10798762]
43. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-432 [PMID: 11172345]
44. Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, Boxall L, O'Donnell K, Shaw J, Hübscher S, Elias E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107-113 [PMID: 10601065]
45. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589 [PMID: 9696028]
46. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902 [PMID: 11451174]
47. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto M. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910 [PMID: 11451175]
48. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW, Martin P. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748 [PMID: 11084061]
49. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11: 716-732 [PMID: 15973718]
50. Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189-1197 [PMID: 22274310 DOI: 10.1016/j.jhep.2011.08.026]
51. Ishigami M, Onishi Y, Kamei H, Kiuchi T, Katano Y, Itoh A, Hirooka Y, Goto H. Impact of recipient age and preoperative fasting blood glucose level as the risk factors of living donor liver transplantation in cirrhotic patients in the recent comprehensive era with knowledge of indications: Recent status in a Japanese single center. Hepatol Res 2013; 43: 1148-1155 [PMID: 23413786 DOI: 10.1111/hepr.12067]
52. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-496 [PMID: 10545536]
53. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, Eggen HJ, Steinbrecher UP. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-525 [PMID: 10545541]
54. Seehofer D, Rayes N, Naumann U, Neuhaus R, Müller AR, Tullius SG, Berg T, Steinmüller T, Bechstein WO, Neuhaus P. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72: 1381-1385 [PMID: 11685107]
55. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-381 [PMID: 17318855]
56. Takaki A, Yagi T, Iwasaki Y, Sadamori H, Matsukawa H, Matsuda H, Shinoura S, Umeda Y, Miyake Y, Terada R, Kobashi H, Sakaguchi K, Tanaka N, Shiratori Y. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83: 231-233 [PMID: 17264822]
57. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given on demand in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203-1208 [PMID: 15114086]
58. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A oneyear trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68 [PMID: 9654535]
59. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-568 [PMID: 10716688]
60. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung NW. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-1282 [PMID: 15482535]
61. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722 [PMID: 14724824]
62. Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22: 387-394 [PMID: 19017304 DOI: 10.1111/j.1432-2277.2008.00784.x]
63. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258 [PMID: 12614278]
64. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134 [PMID: 10869300]
65. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl 2006; 12: S54-S64 [PMID: 17051551]
66. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813 [PMID: 15973721]
67. Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008; 85: 1105-1111 [PMID: 18431229 DOI: 10.1097/TP.0b013e31816a342a]
68. Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, Pulvirenti A, Franchello A, Colombo M, Salizzoni M, Rizzetto M. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-538 [PMID: 15838891]
69. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405-415 [PMID: 18242209 DOI: 10.1053/j.gastro.2007.11.036]
70. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
71. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13: 353-362 [PMID: 23137006 DOI: 10.1111/j.1600-6143.2012.04315.x]
72. Sánchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, Cirera I, Sánchez-Tapias JM, Rodés J. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501 [PMID: 10655276]
73. Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, Lionetti R, Casciani CU, Tisone G. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-181 [PMID: 11786974]
74. Karasu Z, Ozacar T, Akarca U, Ersoz G, Erensoy S, Gunsar F, Kobat A, Tokat Y, Batur Y. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005; 12: 212-215 [PMID: 15720538]
75. Lo CM, Liu CL, Chan SC, Lau GK, Fan ST. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 283-287 [PMID: 15964658]
76. Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, Tillmann HL, Klempnauer J, Strassburg CP, Manns MP. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007; 13: 367-373 [PMID: 17318859]
77. Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, Kokudo N, Omata M, Makuuchi M. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res 2009; 39: 7-13 [PMID: 18761679 DOI: 10.1111/j.1872-034X.2008.00412.x]
78. Bienzle U, Günther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, Neuhaus P. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38: 811-819 [PMID: 14512868]
79. Bauer T, Günther M, Bienzle U, Neuhaus R, Jilg W. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl 2007; 13: 434-442 [PMID: 17318860]
80. Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, Ushitora Y, Ohira M, Banshodani M, Tashiro H, Itamoto T, Asahara T, Imamura M, Takahashi S, Chayama K, Ohdan H. Successful hepatitis B vaccination in liver transplant recipients with donorspecific hyporesponsiveness. Transpl Int 2009; 22: 805-813 [PMID: 19490542 DOI: 10.1111/j.1432-2277.2009.00864.x]
81. Park JB, Kwon CH, Lee KW, Choi GS, Kim DJ, Seo JM, Kim SJ, Joh JW, Lee SK. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int 2008; 21: 346-352 [PMID: 18208419 DOI: 10.1111/j.1432-2277.2007.00618.x]
82. Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK, Lee KU. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37: 1329-1334 [PMID: 12774011]
83. Kwon CH, Suh KS, Yi NJ, Chang SH, Cho YB, Cho JY, Lee HJ, Seo JK, Lee KU. Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant 2006; 10: 479-486 [PMID: 16712607]
84. Soejima Y, Ikegami T, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Yamashita Y, Maehara Y. Hepatitis B vaccination after living donor liver transplantation. Liver Int 2007; 27: 977-982 [PMID: 17696937]
85. Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M, Yasuda Y, Nakayama E, Miyake Y, Ikeda F, Shiraha H, Nouso K, Fujiwara T, Yamamoto K. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol 2013; 48: 1373-1383 [PMID: 23435670 DOI: 10.1007/s00535-013-0763-8]
86. Ishigami M, Kamei H, Nakamura T, Katano Y, Ando H, Kiuchi T, Goto H. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol 2011; 46: 367-377 [PMID: 20835733 DOI: 10.1007/s00535-010-0313-6]
87. Iacob S, Hrehoret D, Matei E, Dorobantu B, Gangone E, Gheorghe L, Popescu I. Costs and efficacy of on demand low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis 2008; 17: 383-388 [PMID: 19104697]
88. Karademir S, Astarcio?lu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A, Akan M, Tankurt E, Astarcio?lu I. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006; 38: 579-583 [PMID: 16549180]
89. Karasu Z, Ozacar T, Akyildiz M, Demirbas T, Arikan C, Kobat A, Akarca U, Ersoz G, Gunsar F, Batur Y, Kilic M, Tokat Y. Lowdose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921-927 [PMID: 15651751]
90. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, Cheng N, Wei Y, Yang J, Xu M, Wang W. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10: 1861-1869 [PMID: 20659092 DOI: 10.1111/j.1600-6143.2010.03208.x]
91. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258 [PMID: 16447195]
92. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS, Emre S, Soldevila-Pico C, Reddy KR, Ishitani MB, Tran TT, Pruett TL, Lok AS. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833 [PMID: 20346062 DOI: 10.1111/j.1600-6143.2010.03046.x]
93. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, Alessandria C, Franchello A, Salizzoni M, Rizzetto M. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409 [PMID: 15776431]
94. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013; 108: 942-948 [PMID: 23629601 DOI: 10.1038/ajg.2013.111]
95. Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, Nishijima N, Takada Y, Uemoto S, Chiba T. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther 2011; 16: 479-487 [PMID: 21685535 DOI: 10.3851/IMP1771]
96. Ishigami M, Honda T, Ishizu Y, Onishi Y, Kamei H, Hayashi K, Ogura Y, Hirooka Y, Goto H. Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients. Liver Transpl 2014; 20: 1211-1220 [PMID: 24961506 DOI: 10.1002/lt.23935]